Related Experiment Video
Updated: Jun 22, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
The role of beta receptor blockade in preventing sudden death
1Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Hospital, Gothenburg University, Sweden.
Insights
Reducing sudden coronary death in hypertensive patients is key. Some beta-blockers, particularly beta 1-selective ones, show promise in preventing sudden cardiac death, independent of blood pressure control.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- High mortality from coronary heart disease in hypertensive patients necessitates reducing sudden cardiac death.
- Current treatments require tailored strategies for high-risk individuals to mitigate sudden death risk.
Purpose of the Study:
- To review treatment strategies aimed at reducing sudden death risk in hypertensive patients.
- To evaluate the efficacy of various antihypertensive drug classes in preventing sudden coronary death.
Main Methods:
- Review of clinical trials and large-scale secondary preventive studies.
- Analysis of data on angiotensin converting enzyme (ACE) inhibitors, calcium antagonists, alpha-blockers, and beta-blockers.
Main Results:
- ACE inhibitors and calcium antagonists have shown disappointing results in preventing sudden death.
- Certain beta-blockers have demonstrated significant reductions in sudden death and other coronary events in both primary and secondary prevention.
- Benefits of some beta-blockers are linked to beta 1-blockade, potentially independent of blood pressure reduction.
Conclusions:
- Not all beta-blockers are equally effective in preventing sudden death; beta 1-selective agents show the most promise.
- Lipophilic beta-blockers with central beta 1-blockade may reduce sudden death risk by enhancing cardiac vagal tone and electrical stability.
Abstract:
The high mortality rate from coronary heart disease in hypertensives can only be substantially reduced if sudden coronary death rates can be decreased. The aim of this review is to discuss how treatment may be tailored to reduce the risk of sudden death in high-risk patients. Clinical trials have not yet produced long-term primary prevention data on the effects of angiotensin converting enzyme (ACE) inhibitors, calcium antagonists or alpha-blockers on cardiovascular complications and sudden death in hypertensive patients. Further, the conclusion from large-scale secondary preventive studies presently available on ACE inhibitors and calcium antagonists is that their impact on sudden death has been disappointing. By contrast, some beta-blockers have reduced sudden death and other coronary events both in primary and secondary preventive studies. The benefits have been attributed to beta 1-blockade, and seem to be independent of blood pressure control. It cannot be assumed that all beta-blockers are equally effective in preventing ventricular fibrillation, sudden death and other coronary events. To date, the best documented data cover the lipophilic beta-blockers and it is speculated that by increasing levels of cardiac vagal tone and electrical stability in the heart, beta 1-blockade in the brain might contribute to the reduction in sudden death risk seen with these beta-blockers.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Action of β1 Blockers
Antihypertensive Drugs: Types of β-Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure Drugs: β-Blockers

